^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
Excerpt:
All patients with FLT3 mutations (n = 4) had morphologic or partial responses compared with 2 of 10 evaluable patients with wild-type FLT3. Responses, although longer in patients with mutated FLT3, were of short duration....Of the 16 enrolled patients, 2 presented with FLT3-ITD (patients 7 and 13) and 2 with FLT3-D835 (patients 3 and 8) mutated receptors at baseline. After 4 weeks of SU11248 treatment, 1 patient with D835 mutation (patient 3) achieved a MorphR and the other 3 achieved PRs.
DOI:
https://doi.org/10.1182/blood-2004-05-1846
